Objective. In the setting of an expanding prevalence of acute pain medicine services and the aggressive use of multimodal analgesia, an overview of systems-based safety gaps and safety concerns in the setting of aggressive multimodal analgesia is provided below.
Introduction
Effective acute pain medicine provides numerous benefits beyond the control of pain intensity, including decreased length of hospitalization, improved sleep, optimization of physical function, and dampening of emotional distress [1] [2] [3] . However, aggressive and comprehensive acute pain management may also cause unintentional harm. Such harm can be in the form of a direct injury following an intervention or as a result of lack of intervention.
When harm is due to intervention, it is often due to treatment-related side effects or complications. Pharmacologically, medications may have a side effect profile that is unfavorable or sometimes even prohibitive in patients. In particular, opioid analgesic use has been the source of multiple guidelines for safe practice, with no current optimal modality for appropriate monitoring and a body of literature that can be overwhelming in its breadth and content. With interventional therapies such as perineural blockade, both drug toxicity (i.e., local anesthetic toxicity) and mechanical injury from a variety of mechanisms (i.e., bleeding, infection, direct neurological injury) are also of concern. Such adverse events inevitably result in significant further health care resource utilization.
Alternatively, lack of intervention to manage pain has its own consequences. More quantifiable are the shortterm physiologic effects of pain such as excessive cardiac sympathetic stimulation, inflammation, and hypercoagulable effects [4] . Emotional distress due to poorly managed acute pain, while less quantifiable, can significantly influence pain and impact recovery [5] . In the long term, ineffective acute pain management has been linked to chronic pain syndromes such as persistent postsurgical pain (PPSP) or phantom limb pain [5] .
These risks related to the presence or absence of adequate acute pain management speak to the complex systems-based infrastructure that must exist in order to adequately apply individual therapies that each maintain a unique risk-benefit profile. In this review, systemsbased gaps are discussed as they relate to patient safety in the setting of acute pain management. Additionally, risks secondary to common pharmacologic therapies are reviewed. Safety concerns related to interventional procedures (e.g., peripheral/neuraxial blockade) have been reviewed extensively in previous publications [6] [7] [8] . Emerging concepts and areas of future research to mitigate systems-based and pharmacologic risks are provided.
Adverse Events in Acute Pain Care Associated with Systems-Based Gaps

Variability in Acute Pain Care
Perioperative care is, for the most part, fragmented with little to no coordination between the services involved. Mackey described the current state of health care delivery as "predominantly autonomous physicians practicing with an individualistic, artisan-like approach" [9] . Acute pain management is no exception; care provided is often based on individual anecdotes and practice patterns for individual physicians rather than adoption of evidence-based management guidelines [10] . This is seen through significant variability in the use of multimodal analgesia across different hospitals around the country and across different surgical procedures [11] . Also, despite evidence for the use of techniques such as perineural blockade, a minority of systems employ such techniques for common surgeries such as total knee arthroplasty [12] .
Factors contributing to such variability can be grouped into patient-, physician-, and nurse-related factors [13] . Knowledge gaps about evidence to support the use of multimodal analgesia, unidimensional pain assessments, and fear of side effects of opioid and nonopioid analgesics are some of these factors. Having dedicated acute pain management services is not always feasible in every institution based on the available resources and the practice model. Although these services have been shown to be cost-effective, some health care systems cannot dedicate financial resources to support this model [14, 15] . The results of this fragmented acute pain management strategy are often inadequate postoperative pain control, a high incidence of adverse effects, readmission rates, and potentially more frequent transition to chronic persistent postsurgical pain [16] .
Gaps in Systems-Based Pain Measurements
For any measurement, established reliability and validity are essential. Once a certain cutoff point, trend, or pattern of such measures emerges, a practitioner must have a matched treatment option that impacts or improves such a specific measure. Additionally, such medical measurements must be able to capture the complexity of the particular condition. If they are absent, complications related to under/overtreatment may occur.
Before consideration is given to the safety of analgesic agents, the question of whether current pain measurement methods adequately guide analgesic choices must be entertained. However, further clinical evaluation has revealed shortcomings with a unidimensional approach to acute pain measurement. While guidelines such as the World Health Organization analgesic ladder segregate analgesic choices by pain severity, it has become increasingly clear that such cutoff points are vague when using unidimensional scales. While a numerical rating score of >4 may be a trigger for analgesic prescription in some studies, scores >3 are quoted in others [24, 25] . Further, van Dijk et al. surveyed more than 10,000 patients in the postoperative setting and found that 65% of patients reporting NRS scores of 4-6 (moderate to borderline severe) found their pain tolerable and refused further analgesics [21] . Of note, acute pain nurses notably overestimated patients' pain in this study when compared with patient-reported scores when using the NRS. In a follow-up study by van Dijk, the median NRS score for which patients would desire opioid analgesics was a score of 8, which is notably higher than what is quoted in a variety of guidelines [26] . Thus, not only are pain severity cutoffs vague, but matched analgesic regimens do not necessarily correspond to patients' needs. Additionally, there are no data that link the severity of the score to the aforementioned outcomes.
Reliance on unidimensional pain intensity scales also impairs the ability to assess treatment response and does not take into consideration the impact of other pain-related variables. While a decrease in NRS scores In order to decrease the probability of under/overtreatment, multidimensional measures of pain may provide the ability to assess the full biopsychosocial nature of acute pain and focus analgesic regimens toward contributing variables of acute pain rather than simply the sensory component (i.e., pain intensity Additionally, an unforeseen consequence pertaining to opioid misuse has arisen during this transitional period. Directly following discharge, the majority of patients do not utilize their entire opioid prescription and are left with a sizeable stock of leftover opioid that is not returned [54] [55] [56] [57] . As >50% of pain medicine used for nonmedical uses is obtained from a friend/relative, opioid overprescription in the perioperative period may provide a significant contribution to societal opioid diversion [58] .
Recently, a group at the University of Toronto described the use of such a transitional pain service focused on not only addressing pain intensity at time of discharge but also comprehensive services for inpatients aimed at minimizing opioid usage following discharge [44, 59] . Such a transitional pain service provides a biopsychosocial focus addressing both the physiologic and psychologic components of perioperative pain. Patients are engaged prior to discharge and followed postdischarge with the goal of transitioning pain management to a primary provider by three months. While the impact of such services has not been formally scrutinized, it provides a promising path forward to bridge this safety gap in acute pain medicine.
Perioperative Surgical Home
Hospital-level intervention has been suggested as the ideal step to increase the adoption of acute pain care [11, 13] . Acute pain services should be responsible for implementation of multimodal analgesia protocols and should take part in educating nurses and other health care providers about their benefits [60] .
Under the current surgical care paradigm, transition of care between providers and facilities also tends to be poorly coordinated. One of the emerging promising models is the perioperative surgical home (PSH), which is a patient-centered, physician-led, multidisciplinary, team-based system of coordinated care [61] . At its core, PSH aims to decrease systems-related variability and incorporate evidence-based guidelines. The PSH model is designed to coordinate patient care throughout the entire surgical experience, starting from the decision for surgery through discharge from a medical facility and beyond [62] . A growing evidence base supports the PSH model improving variables such as length of stay and unplanned hospital admissions [63, 64] .
Acute pain management is one of the key components of the PSH [65] . Recently, the PSH model has shown promise to substantially decrease variability and improve multimodal adherence within a bilateral knee arthroplasty population [66] . The implementation of such total joint-PSH pathways has resulted in decreased direct hospital costs below the US benchmark level as well as decreased length of stay [67] . Under the umbrella of this model, an evidence-based care pathway should be adopted and applied to the majority of patients. However, there are patients who are outliers and at higher risk for the development of severe postoperative pain and should be identified through screening and prediction tools. Criteria used for screening should include a history of chronic opioids or other substance abuse, high catastrophizing score, anxiety, depression, and other psychological disorders [45, 68] . Pain physicians or primary care providers should be engaged in scheduling patients for surgery to provide specific recommendations regarding preoperative optimization, in designing more targeted pain management strategies, and in planning for follow-up care after discharge. Identifying these patients or following them up requires an adequate informational technological infrastructure, which is another investment in and of itself that health systems must embrace.
Risks Attributable to Common Pharmacologic Therapies
Opioid-Based Adverse Events
Opioid analgesics have been the mainstay for treatment of moderate to severe postoperative pain for decades, despite well-characterized serious side effects that can lead to substantial morbidity and mortality. In the last 15 years, in response to the pain management standards set by the Joint Commission, there has been an unprecedented increase in perioperative opioid administration to control postoperative pain [36, 69] . Not surprisingly, concerns were raised that this practice shift has increased the incidence of oversedation and fatal respiratory events [70, 71] . These concerns came to realization, and now opioids are among the most commonly implicated class of medications with serious adverse events in hospitalized patients [72] . Though opioid-associated adverse side effects are numerous and problematic, respiratory depression garners the most attention because it is a potentially lethal effect of these drugs [73] .
Respiratory Depression
Mu-receptor-mediated respiratory depression is the most commonly recognized serious side effect of these drugs and is the primary culprit of opioid-associated serious morbidity and mortality [72] . The incidence of opioid-induced respiratory depression is widely cited to be 0.5% in postoperative patients [74] . However, this value may not be accurate because studies vary on definitions of respiratory depression (hypoxemia vs hypopnea) or rely on retrospective data, which could underestimate the true incidence. A prospective study from Cleveland Clinic where noncardiac surgical patients were continuously monitored with pulse oximetry found that 21% had an oxyhemoglobin saturation (SPO 2 ) of 90% for an average of 10 minutes/h and 8% had an average of 20 minutes/h; further, 8% had SPO 2 <85% for 5 minutes/h [75] . Furthermore, 3% of postsurgical patients had SPO 2 <80% for 30 minutes [75] . A smaller study of 178 postsurgical patients selfadministering opioids using a patient-controlled analgesic (PCA) device found that 12% had oxyhemoglobin desaturations of <90% and 41% had hypopnea (<10 breaths per minute) for greater than three minutes [76] .
The degree of oxyhemoglobin desaturation that characterizes clinically relevant hypoxemia due to opioidinduced respiratory depression has varied in the literature [77, 78] . Further, reliance on hypoxemia to identify opioid-induced respiratory depression in many studies is problematic. Arterial blood oxygen saturation is primarily a measure of gas exchange that occurs in the lungs. Under normal circumstances, the development of hypoxemia reasonably reflects the development of respiratory depression [79] . However, even a slight increase in the percentage of inspired oxygen delays the development of hypoxemia in the setting of profound respiratory depression [79] . The widespread practice of the application of supplemental oxygen to postoperative patients calls into question the reliance of pulse oximetry as the standard monitor to detect opioid-induced respiratory depression [80] . However, a recent study from Dartmouth showed that 71% of all oxygen saturations of less than 90% were associated with normal respiratory rates of 12 to 20, along with no demonstrable improved patient outcomes when adding continuous respiratory rate monitoring to existing pulse oximetry monitoring [81] . At present, there is no evidence showing that the reliance of oxygen saturation monitoring for patients on oxygen can be improved by adding another sensor [81] . As seen below, continuous pulse oximetry can result in significant benefits, such as early detection and avoidance of care escalation. When used in a standard systems-based fashion, oxygen saturation is clearly better than the absence of any monitoring at all.
Despite calls for continuous monitoring on all postoperative patients administered opioid analgesics, assessments for respiratory depression typically rely on intermittent nursing assessments. Technologies such as bedside capnography, acoustic respiratory rate monitoring, impedance pneumography, respiratory inductance plethsmography, and next-generation pulse oximeters that can calculate respiratory effort are emerging [82, 83] . Such novel monitors of respiratory effort may be better suited to monitoring postoperative respiratory depression because hypoxemia is only a surrogate variable. However, technologies to monitor these variables are not currently widely adopted in clinical settings.
Naloxone, a nonselective antagonist of the major opioid receptors, is the major antidote used in the United States to treat opioid-induced respiratory depression and oversedation. Naloxone administration provides an alternative method for identifying patients who had severe episodes of narcotization, which can be used to estimate the incidence of "serious" or "life-threatening" opioid-induced respiratory depression [84] . A study of postoperative patients at the Mayo Clinic found that the incidence rate of emergent naloxone administration to reverse opioid-induced sedation or respiratory depression was 1.6 per 1,000 (95% confidence interval ¼ 1.3-1.9) anesthetics, which provides a reasonable estimate of patients affected by dangerous levels of overnarcotization [85] . Several studies have found that the majority of naloxone administrations occur during the first postoperative day, often within the first 12 postoperative hours, indicating that this early postoperative period is especially high-risk for life-threatening complications from postoperative opioid analgesics [86] .
Many patient characteristics have been identified that increase the risk for opioid-induced sedation. Some of these include surgery involving the upper abdomen or thorax, greater administration of opioids and coadministration of other sedating medications, a high disease burden, and age [85] . Obstructive sleep apnea (OSA) has garnered substantial attention for placing patients at increased risk for opioid-induced respiratory depression [84, 85, 87] . There is a high prevalence of OSA among obese surgical patients, and in a substantial proportion of surgical patients, OSA has not been diagnosed preoperatively [88] [89] [90] . This is concerning because the increased prevalence of obesity in the general population has translated into an increased incidence of obese patients in surgical practice [91] .
Therefore, it has been advocated that all surgical patients be preoperatively screened for OSA, with the goal of then using the test results to tailor the perioperative management of high-risk patients [92] .
Typically, opioids induce respiratory depression in a dose-dependent manner with antecedent sedation. However, oxyhemoglobin desaturations and hypopnea are still common with these devices, especially when a basal infusion of opioid is included [76] . Methadone has recently garnered some attention as an analgesic for major surgery where it is administered as a single preoperative dose [93] . The clinician needs to be aware that methadone has a highly variable half-life, is metabolized through multiple P450 cytochromes, and has many potential drug-drug interactions (see below). These pharmacokinetics are responsible for the observation that repeated doses of methadone result in plasma accumulation and a prolonged time to reach steady state. The many variables that need to be considered to safely use or prescribe methadone in acute pain and chronic pain realms are likely behind the disproportionate number of opioid-related overdose deaths [94, 95] . Until more studies are performed establishing the safety of perioperative methadone, thoughtful deliberation should be exercised prior to administration of methadone in patients naïve to the drug, especially with repeated doses.
Neurologic Toxicity
All opioids can induce sedation and cognitive impairment and, with chronic use, physical and psychological dependence. In addition to these, opioids can have neuro-excitatory effects. The synthetic phenylpiperidine opioid meperidine undergoes hepatic metabolism by Ndemethylation to normeperidine catalyzed by cytochrome P450 CYP2B6 and CYP3A4 isoenzymes [96] . The elimination of normeperidine is considerably longer than that of meperidine. Normeperidine causes central nervous system excitation, which can result in generalized seizures [97] . In addition, meperidine and other phenylpiperidine opioids such as fentanyl and remifentanil have serotonergic properties vis-a-vis facilitating the release of serotonin from presynaptic neurons and weakly inhibiting serotonin reuptake from the synaptic cleft. Phenylpiperdine opioids on rare occasion have been implicated in the development of serotonin syndrome, albeit in patients coadministered other serotonergic medications such as serotonin reuptake inhibitors or monoamine oxidase inhibitors [98] [99] [100] [101] . Anesthesiologists should consider patients' preoperative medications to assess the risk for serotonin toxicity. Lastly, chronic exposure to opioids can lead to the development of paradoxical hyperalgesia, which is mediated, in part, by activation of the central glutaminergic pathway via N-methyl D-aspartate (NMDA) receptors [102] . Short infusions of higher doses of remifentanil have been demonstrated to result in hyperalgesic responses [49] . The use of the NMDA antagonist ketamine has been shown to mitigate the effects of opioidinduced hyperalgesia in the clinical setting [103, 104] .
Cardiac Effects
The most commonly encountered cardiac effects from perioperative opioids are the development of bradycardia and hypotension, and these are most associated with the use of remifentanil [105] . Remifentanil-induced bradycardia appears to be mediated, in part, by effects on the cardiac conduction system and negative chronotropic effects [106] [107] [108] .
Methadone is the other opioid with a notable cardiac effect, the prolongation of the QTc vis-a-vis inhibition of the cardiac potassium channel hERG, and can lead to the development of torsade de pointes [109, 110] . Because methadone is primarily metabolized by CYP3A4, liver dysfunction, hypokalemia, or coadministration of inhibitors of CYP3A4 (e.g., amiodarone, cimetidine, midazolam, dexamethasone, diltiazem, serotonin reuptake inhibitors, protease inhibitors, macrolide antimicrobials, cyclosporine, omeprazole, valproic acid) alter the pharmacokinetics of methadone and increase the risk [111] . Its use with other medications is also known to also prolong the QTc (e.g., tricyclic antidepressants, cocaine, and butyrophenone antipsychotics) [112] .
Altered Metabolism with Cytochrome P-450 Induction, Inhibition, and Genetic Variability Many opioids are metabolized by the hepatic cytochrome P450 system, a pathway that can be inhibited or induced by medications. For example, inhibition of the Cytochrome P450 3A isoenzymes can interfere with the metabolism of methadone, alfentanil, and fentanyl (e.g., diazepam, see previous list) [111, 113, 114] .
Conversely, inhibition of the cytochrome P450 system can limit the effectiveness of certain opioids. Tramadol, for example, is a prodrug that undergoes hepatic O-demethylation by the cytochrome P450 CYP2D6 into its active form of O-desmethyltramadol [115] . Similarly, codeine undergoes O-demethylation and is converted to morphine by CYP2D6. Inhibition of CYP2D6 by medications such as serotonin reuptake inhibitors (especially paroxetine and fluoxetine) can diminish the analgesic activity of tramadol and codeine [116, 117] .
Polymorphism of the Cytochrome P-450 exists, notably with CYP2D (10% of Caucasians), which converts codeine to morphine. This leads to unpredictable responses to codeine, ranging from absent analgesic response (poor CYP2D6 metabolism) to codeine intoxication (ultrarapid CYP2D6 metabolism) [118, 119] . Polymorphism of the CYP3A4 (CYP3A4*1 G) in the Chinese population has been shown to slow the metabolism of fentanyl [120] .
Nonopioid Adjunct-Specific Adverse Events
Acetaminophen/N-Acetyl-Para-Amino-Phenol/ Paracetamol While acetaminophen has the most benign side effect profile when taken in recommended doses, acetaminophen overdose is the leading cause of acute hepatic failure in the United States and Europe [121] . Unfortunately, unintentional overdoses occur due to the multiple different combinations of drugs that include acetaminophen, such as acetaminophenin combination with hydrocodone (Lortab, Vicodin, Norco), oxycodone (Percocet, Roxicet), butalbital/caffeine (Fioricet), and tramadol (Ultracet). Patients with chronically decreased hepatic function (e.g., malnutrition, hepatitis C, alcoholism) may take acetaminophen with relative safety, though the lowest effective dose for the shortest duration should be considered [122] .
Acetaminophen's safety can also be evaluated by its ability to decrease the need for opioids in the acute setting. As a monotherapy adjunct for pain management, acetaminophen does not provide as much opioid sparing compared with nonsteroidal anti-inflammatory drugs (NSAIDs) and gabapentin [123] [124] [125] . However, when combined with NSAIDs, a significantly larger opioidsparing effect is observed [126] . Recently, intravenous acetaminophen has been become available in the United States. In certain clinical situations, this route has theoretical pharmacokinetic benefits that may make it more efficacious than the traditional oral or rectal routes of administration. However, an opioid-sparing benefit has been observed to range from insignificant to a 45% reduction in surgical procedures with moderate to severe pain intensity [125, [127] [128] [129] [130] [131] . Without a reduction in opioid-related adverse events and the 30-to 100-fold increase in cost of intravenous compared with oral dose, intravenous use may not be justified by the modest improvement in pain scores.
Gabapentanoids
While the use of gabapentin for perioperative pain management has been studied extensively, many studies have been characterized by small sample sizes, and optimal surgery-specific dose and duration of therapy have not been established [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] . In a recent meta-analysis by Fabritius et al. of 135 trials where trials were stratified by risk of bias, the authors concluded that a clinically relevant benefit of gabapentin was absent when only considering low-bias studies [144] . In the setting of such heterogeneity, the efficacy of gabapentin on postop pain control cannot be universally established, and thus individualized risk/benefit considerations should occur [122] .
Notable side effects of gabapentin have been well documented with long-term therapy, such as dizziness, Safety in Acute Pain Medicine sedation, gait disturbance, headache, difficulty with concentration, peripheral edema, and visual disturbances [145] [146] [147] . In the perioperative setting, most trials conducted on the use of gabapentin assess for a few of gabapentin's known adverse effects, most commonly sedation/somnolence, dizziness, and visual disturbances (Table 1) [148] . The incidence of nausea and vomiting was not noted to be significantly reduced with perioperative gabapentin use, though concurrent postoperative opioid use is a significant confounder that obscures the true occurrence of these symptoms with gabapentin. Though Fabritius' comprehensive systematic review concluded no increased risk of sedation and dizziness with short-duration gabapentinoids in low-bias studies, the true incidence may be underestimated as side effects were only monitored within the first 24 postoperative hours [144] . Anesthesia and use of other sedatives (benzodiazepines, opioids) in the acute postoperative setting may mask gabapentinoids' effects on sedation and dizziness. With minimal to modest analgesic efficacy for perioperative pain, it would be prudent to reserve use of gabapentinoids for those patients at significant risk of neuropathic pain (i.e., amputation, major tumor resection, spine surgery). Caution should be exercised in patients at risk for cognitive dysfunction (elderly patients, altered mental status), outpatient surgery, patients at risk for falls, and patients with renal dysfunction.
Nonsteroidal Anti-inflammatory Drugs
While NSAIDS do not share the side effect profile of opioids, their side effects are no less significant. NSAIDS, whether selective toward cyclo-oxygenase-1 (COX-1) or cyclo-oxgyenase-2 (COX-2), have the potential to affect hematologic, cardiovascular (CV), gastrointestinal (GI), and renal systems upon initiation of NSAID treatment or when taken consistently for a period of greater than one or two weeks [150] .
Cardiovascular Risk
Selective COX-2 inhibitors (celecoxib, rofecoxib [withdrawn from the market], valdecoxib [withdrawn], etoricoxib, lumiracoxib [withdrawn], parecoxib, etodolac, meloxicam) have been under intense scrutiny for an increased incidence of myocardial infarction and strokes, most notably with rofecoxib [151] [152] [153] . Selective COX-2 inhibition results in reduced prostacyclin-mediated endothelial smooth muscle relaxation, vasodilation, and inhibition of platelet adhesion and aggregation while leaving thromboxane A2-mediated platelet aggregation intact, leading to an increased risk of myocardial and cerebral thrombotic events [154, 155] . Celecoxib is currently the only available selective Cox-2 inhibitor in the United States (maximum dose of 200 mg/d) and has a cardiovascular risk similar to that of nonselective NSAIDs (though it has a black box warning for cardiovascular thrombotic events) [156] [157] [158] [159] .
While some NSAIDS such as naproxen have been suggested to have benign cardiovascular profiles, this was recently called into question in a Bayesian meta-analysis of individual patient data [150, 160] . In 446,763 patients, concurrent use of NSAIDs was significantly associated with acute myocardial infarction. While the population studied differed from acute pain patients, peak risk [148] , which examined rates of adverse events from systematic reviews of meta-analyses of data. † Data from Moore et al. [146] . ‡ Data from Meng [149] .
occurred within the first 30 days of the initiation of NSAIDS. Of note, naproxen did not confer any less risk when compared with other NSAIDs studied.
Though the initial emphasis on cardiovascular thrombotic events was on selective COX-2 inhibitors, all NSAIDs can affect the cardiovascular system and increase blood pressure. This is speculated to be due to influences on sodium balance and natriuresis as well as peripheral vasoconstriction (inhibition of prostacyclinmediated endothelial smooth muscle relaxation and vasodilation) [161, 162] . These physiologic effects lead to a 24% higher risk of heart failure, most notably in patients using long-term (uninterrupted for at least one year) ketorolac, indomethacin, rofecoxib, piroxicam, and diclofenac [163] [164] [165] .
Gastrointestinal Risk
Gastric erosion and ulceration of the upper and, less commonly, the lower GI tract have been a major source of morbidity in patients with risk factors (history of peptic ulcer disease, increasing age, concomitant use of other NSAID/steroid/anticoagulant, presence of Helicobacter pylori) [166] [167] [168] . Clinically serious GI events such as gastrointestinal bleeding, perforation, or obstruction occur in approximately 0.5% of annual NSAID users [169] . While selective COX-2 inhibitors have reduced the risk of GI erosion, ulceration, and perforation as compared with nonselective COX inhibitors, they have not matched those of placebo [151, 158, 166, 170, 171] . However, use of selective COX-2 inhibitors appears to be as or more effective in reducing GI adverse effects when compared with combination of nonselective inhibitors and gastric protective agents (H2 blockers, proton pump inhibitors) [171] [172] [173] . Compared with nonusers of NSAIDs, patients who use ibuprofen, naproxen, and diclofenac have a relative risk of upper GI bleed of 4.1, 7.3, and 3.1, respectively [172, 174] . The risk is greatest for the use of naproxen and least for celecoxib as compared with other NSAIDs [175] .
Renal Risk
All NSAIDs, regardless of COX selectivity, may negatively impact renal function through afferent arteriolar constriction, glomerular filtration rate (GFR) reduction, and inhibition of kidney excretion of salt and water [173, 176, 177] . Acute kidney injury due to COX-2 inhibition results in volume overload, hyponatremia, and hypokalemia, though this is usually reversible with NSAID discontinuation [178] . In patients with minimal comorbidities, NSAID use postoperatively resulted in a clinically insignificant reduction in renal function [179] . NSAID use in the acute setting should be limited or avoided altogether in patients with chronic kidney disease (CKD) or effective low blood volume (vomiting, heart failure, hemorrhage, etc.) due to concerns for acute kidney injury [180] . As NSAIDs inhibit prostaglandin-mediated renin release, their use should be limited in patients on ACE inhibitors, angiotensin II receptor blockers, and diabetics [178, 181] . If NSAIDs are prescribed in the above settings, creatinine monitoring should occur.
Bone Healing
In a variety of animal studies, NSAIDs have been associated with delayed bone healing due to prostaglandin inhibition and a possible decrease in osteoblastic activity, although other mechanisms have been suggested [182, 183] . However, many animal studies have shown no relation between NSAID use and bone healing and have suggested that type, dose, and duration may also play a role [184] . In humans, numerous retrospective studies have suggested that NSAIDS delay bone healing in a variety of fracture types [185] . However, few prospective randomized trials have been conducted, and they have shown contradictory results, albeit in different fractures [186, 187] . Further research is warranted in this area to elucidate the effect of NSAIDs on bone healing, the role of short-term use, and if any measurable inhibition of bone healing is reversible following cessation of NSAID use. While short-term use is unlikely harmful, NSAID use following orthopedic trauma should be administered on a case-by-case basis with close communication with surgical services considering both analgesic benefits and possible risks.
Ketamine
Intravenous administration of ketamine within the perioperative period has been shown to decrease both pain intensity scores and opioid use in numerous studies across a variety of surgical subtypes [188] . Ketamine maintains an excellent side effect profile when administered within a perioperative infusion strategy (typically no more than 300 mcg/kg/h). While ketamine has been marred by a historical stigma of excessive cardiovascular, psychomimetic, and neurologic detriments, a growing number of institutions support its use in the extended postoperative period outside of a perioperative or intensive care setting.
A variety of studies have documented central nervous symptoms (e.g., excitation, sedation, hallucination) occurring in upwards of 20% of patients receiving perioperative infusions [189, 190] . However, when compared with controls, the majority of studies display no significant difference, and central nervous symptoms almost universally subside in a short amount of time following cessation of infusion [189] . Ketamine is often thought to significantly increase sympathetic outflow and predispose patients to tachycardia and hypertension. However, while these phenomena may occur at anesthetic doses, subanesthetic infusions have no significant cardiovascular impact [191] . Similarly, no significant respiratory or gastrointestinal symptoms (e.g., nausea)
Safety in Acute Pain Medicine occur with subanesthetic dosing [191] . However, while ketamine has shown no hepatic detriment in short-term perioperative dosing, small case series have observed liver toxicity in chronic recreational use or prolonged infusions (>100 hours) [192, 193] .
Recently, ketamine's detrimental impact in the setting of acute brain injury has also been called into question.
Traditionally, ketamine has been considered relatively contraindicated in this setting due to presumed increased in intracranial pressure. However, when normocarbia is maintained, this physiologic scenario is no longer considered dogma [194] . In fact, ketamine has been suggested to have a possible neuroprotective role in adult acute brain injury by suppression of excitotoxicity, decreased apoptosis, anti-inflammatory properties, and possible antithrombotic properties via antiplatelet action [194] . While more research is needed, the analgesic use of ketamine in patients with comorbid intracranial pathology should be considered on a case-bycase basis, considering the weight of possible analgesic benefits, instead of universally avoided.
Emerging Concepts in Pharmacologic Safety
Opioids Postoperatively, patients on opioids represent a population at risk for respiratory depression. Postoperative respiratory depression represents nearly 11% of all inpatient safety events and has the highest mortality rate per 100 discharges. This increased risk prompted the Anesthesia Patient Safety Foundation to advocate continuous electronic physiologic monitoring for all inpatients receiving postoperative opioids [76, [195] [196] [197] .
Surveillance
Principles. Continuous monitoring of patients with notifications of providers has been successfully implemented, resulting in reduced adverse events [198] [199] [200] . According to the Joint Commission's Sentinel Event database (2004-2011), 47% of respiratory depression events were wrong dosing medication errors, 29% were related to improper monitoring of the patient, and 11% were related to other factors including excessive dosing, medication interactions, and adverse drug reactions [72] . These data provide some insight into why risk stratification and selective individual monitoring have failed as individual risk profiles do not account for the entire risk environment; in the example of postoperative respiratory depression, almost half of events are related to medication administration (not ordering) error. Future mitigation of drug errors by bar coding medication and their administration as well as medication reconciliation efforts may minimize adverse respiratory events and make selected monitoring a viable option in the future. But currently, risk stratification based on patients' comorbidities falls short as it does not take the clinical environment into account. Furthermore, when experts were asked to select patients who should have had selective monitoring based on their comorbidities after adverse events, the degree of agreement was about 50%, as in a coin toss [201] . Given pervasive systems-based variables and imprecise predictability based on clinical factors, the continuous monitoring of all patients (vs a selected group based on individual risk stratification) was proposed a decade ago [198, 199] .
Using a pulse oximetry surveillance system in an orthopedic inpatient unit, a research group at Dartmouth decreased unanticipated intensive care unit transfers by 50% and activations of the rapid response by 65%. Using a static alarm-based threshold system for heart rate and oxygen saturation, the system redirects the attention of nursing staff to these physiologic deteriorations via a paging system, prompting early intervention [198] . Routine surveillance via pulse oximetry for all inpatients in general care units has been institutional policy at Dartmouth since 2009. No hypoxic brain injury or death has occurred in the original study unit since 2007 [200] . The introduction of a continuous surveillance approach is generally limited to the inpatient population, and efforts to expand surveillance to wireless monitoring and postdischarge monitoring at home are in the research phase. However, as the inpatient length of stay has been reduced for many procedures (e.g., total knee replacement from two nights to short stay and ambulatory procedures), the desire to monitor patients after discharge has also emerged [202] .
Sensors. Careful consideration of available sensors must be taken into account when choosing physiologic variables that will be monitored. When used in a lowacuity setting like a general care unit, the sensors' precision and accuracy as well as comfort to the patient are of great importance. While it is desirable to continuously monitor minute ventilation or tidal volumes in nonintubated patients, a sensor that has patient tolerance and performance characteristics to make it useable for continuous monitoring does not exist. Tracking arterial carbon dioxide likely would provide information regarding hypoventilation, but all that is available currently is an approximation of exhaled carbon dioxide via nasal cannula, which poorly reflects arterial carbon dioxide and is not well tolerated by patients who are awake [76, 200] . Measuring respiratory rate via a sound-based sensor, while technically feasible, is moderately well tolerated by the patient but does not currently improve outcomes when used in addition to an existing pulse oximetry network [81] . Future technological advancements such as transcutaneous carbon dioxide measurement when meeting criteria regarding accuracy and precision hopefully will provide additional benefit beyond pulse oximetry alone. As we consider monitoring systems as a whole, the benefit of each individual sensor needs to be weighed. For example, in the setting of three sensors that each have a specificity of 0.8, the systems overall performance is 0.8 3 ¼ 0.5.
Supervision. Using continuous monitoring outside of the hospital environment as a continuation of care carries a vast, mostly unexplored, set of problems with it that finds its analogy in population health as well. However, while the control of compliance with glucose control does not need to be of high temporal resolution and the immediate impact of noncompliance is low, remotely monitoring respiratory status requires fine-grained supervision and a closed loop and timely response for intervention. These challenges, along with legal, financial, and logistical matters, are starting to be explored in some health care systems that go beyond using telemedicine for consultation.
Opioid Sensitivity Prediction
Clinicians are aware of variation in response to opioids, and advances in pharmacogenetics have provided the scientific background for these variations. The FDA has recommended not to use codeine after tonsil-or adenoidectomies based on DNA variations in cytochrome P450 2D6, where ultrarapid metabolizers experience much higher conversion to morphine conversion and plasma levels. The estimated number of such ultrarapid metabolizers is thought to be one to seven in 100 people [203] . For medications that can cause respiratory depression, bedside tests for metabolic capacity (as available for Plavix) would be desirable as doses or administration intervals could be adjusted to optimize safety.
Nonopioid Analgesics
Aggressive nonopioid multimodal analgesia across numerous surgical subtypes has resulted in welldocumented benefits such as reductions in pain intensity, minimization of opioid dosing, reduction in opioid side effects, and a host of other clinically relevant variables [204, 205] . However, as noted above, each nonopioid adjunct is characterized by its own side effect profile that differentially impacts patients depending on variables such as age, gender, and comorbidities. While many studies have shown that combination nonopioid therapy improves outcomes following surgery, these results are not universal.
For example, Gilron et al. investigated triple vs double drug therapy in postoperative hysterectomy pain with different combinations of meloxicam, acetaminophen, and gabapentin. No significant differences were detected with cough-evoked pain between any group [206] . Additionally, Gilron et al. demonstrated no analgesic benefit with the combination of meloxicam and gabapentin in laparoscopic cholecystectomy compared with each agent alone [207] . These two studies highlight the issue that little is known about the weighted benefit of multimodal analgesics when used together in a surgery-specific manner. Future work into surgeryspecific nociceptive mechanisms, pharmacogenomics, and the comparison of analgesic regimens is needed in order to personalize analgesic therapy and prevent scenarios where patients may be exposed to ineffective agents but still experience their side effects.
Conclusion and Future Considerations
The specialty of acute pain medicine continues to play a growing and essential role in not only optimizing strategies to alleviate acute suffering but also the continued rehabilitative processes during the postacute phase. An impressive body of literature and guidelines support the efficacy of opioid and nonopioid agents in the acute inpatient setting. While a variety of pharmacologic agents are available, so are a host of safety concerns that must be comprehensively understood in order to render adequate and safe acute pain medicine. In the setting of opioids, a multisystem approach should be undertaken as well as investment in systems-based processes to mitigate tragic adverse events. Nonopioid agents, while effective in minimizing reliance on opioids alone, must also be applied with appropriate caution in a patientand comorbidity-specific fashion. Finally, the administration of any pharmacologic or interventional therapy will not reach full potential unless systems embrace accurate pain assessment/diagnosis, consistent analgesic application, and investment in longitudinal pain care models. 
